A Study of TMC435 in Combination With Peginterferon Alfa-2A and Ribavirin for Hepatitis C Virus Genotype-1 Infected Patients Who Participated in a Control Group of a TMC435 Study

• Status: Completed
• Trial end date: 2015-03-01

Summary

The purpose of this study is to investigate the efficacy of a treatment with TMC435 in combination with peginterferon alfa-2a and ribavirin in patients who did not clear their hepatitis C infection with peginterferon alfa-2a and ribavirin alone within a previous trial conducted by Tibotec, or who participated in Tibotec trials in which antivirals directed against hepatitis C virus (HCV) were evaluated for short periods of time.

• Phase: Phase 3

Details

• Lead Sponsor: Janssen R&D Ireland
• Treatments: Interferon-alpha; Peginterferon alfa-2a; Ribavirin; Simeprevir